Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Coming therapies: abacavir.

¹Johann Wolfgang Goethe-University, Frankfurt am Main, Germany.

International Journal of Clinical Practice. Supplement

|January 6, 2000

Summary

Abacavir, a nucleoside analogue reverse transcriptase inhibitor (NRTI), effectively reduces viral load and increases CD4 counts in HIV patients. Its favorable metabolism and potency make it a valuable option for combination therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment: results of a 48-week open-label study.

European journal of medical research·2011

Same author

Mutations in the C-terminal region of the HIV-1 reverse transcriptase and their correlation with drug resistance associated mutations and antiviral treatment.

European journal of medical research·2010

Same author

Human immunodeficiency virus type-1 group M quasispecies evolution: diversity and divergence in patients co-infected with active tuberculosis.

Medical microbiology and immunology·2010

Same author

Intensification of a failing regimen with zidovudine may cause sustained virologic suppression in the presence of resensitising mutations including K65R.

The Journal of infection·2010

Same author

The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive Individuals.

European journal of medical research·2010

Same author

Factors associated with viral rebound among highly treatment-experienced HIV-positive patients who have achieved viral suppression.

HIV medicine·2008

Area of Science:

Pharmacology
Virology
Immunology

Background:

Abacavir is a nucleoside analogue reverse transcriptase inhibitor (NRTI) used in HIV treatment.
It exhibits good oral bioavailability and central nervous system penetration.
Abacavir metabolism bypasses cytochrome P450, minimizing drug-drug interactions.

Purpose of the Study:

To evaluate the efficacy and tolerability of abacavir in HIV-infected patients.
To assess abacavir's role in various combination antiretroviral therapy regimens.

Main Methods:

Review of clinical data on abacavir's pharmacokinetic and pharmacodynamic properties.
Analysis of viral load and CD4 count changes in patients receiving abacavir-containing regimens.
Assessment of adverse events, particularly hypersensitivity reactions.

Main Results:

Abacavir demonstrates antiviral potency comparable to protease inhibitors (PIs) or dual nucleoside combinations.
Significant reductions in viral load and increases in CD4 counts were observed, especially in NRTI-naïve patients.
Hypersensitivity reactions occurred in approximately 3% of patients, leading to treatment discontinuation.

Conclusions:

Abacavir is an effective component of combination antiretroviral therapy for HIV infection.
It offers a valuable option for first- and second-line regimens, including PI-sparing strategies.
While generally well-tolerated, monitoring for hypersensitivity reactions is crucial.

Related Experiment Videos